Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
Eisai presented clinical research in gynecologic oncology during the International Gynecologic Cancer Society (IGCS) 2025 Annual Global Meeting, held in Cape Town, South Africa from November 5 to 7.
The presentations included:
- Long-term follow-up data from the pivotal Phase 3 Study 309/KEYNOTE-775 trial evaluating lenvatinib plus pembrolizumab in patients with advanced endometrial carcinoma.
- Efficacy outcomes in patients with advanced endometrial carcinoma who received prior (neo)adjuvant therapy from Phase 3 Study 309/KEYNOTE-775 and LEAP-001 trials.
- Real-world evidence evaluating the use of lenvatinib plus pembrolizumab versus single-agent chemotherapy in U.S. patients with pMMR/non-MSI-H recurrent or advanced endometrial carcinoma.
Dr. Corina Dutcus, Senior Vice President, Oncology Global Clinical Development Lead at Eisai Inc., stated, "The data we're presenting at IGCS 2025 offer significant insights that help to further the understanding of treatment for endometrial cancer."
Additional research to be presented includes real-world clinical outcomes data examining the comparative effectiveness of lenvatinib plus pembrolizumab versus single-agent chemotherapy in patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) in the United States.
Eisai also presented an analysis of outcomes with lenvatinib plus pembrolizumab versus chemotherapy in patients with advanced or recurrent endometrial carcinoma whose only prior therapy was (neo)adjuvant therapy.
The company's commitment to advanced endometrial cancer care is evident through these presentations, showcasing their dedication to providing innovative treatments and advancing the understanding of endometrial cancer.
